Reported Sunday, Lilly's Jaypirca Plus Venetoclax And Rituximab Reduces Risk Of Disease Progression Or Death By 45% Versus Venetoclax And Rituximab Alone In Previously Treated CLL/SLL Phase 3 Study

뉴스 본문을 불러오고 있어요.

Reported Sunday, Lilly's Jaypirca Plus Venetoclax And Rituximab Reduces Risk Of Disease Progression Or Death By 45% Versus Venetoclax And Rituximab Alone In Previously Treated CLL/SLL Phase 3 Study | 웨이프 WAPE

Reported Sunday, Lilly's Jaypirca Plus Venetoclax And Rituximab Reduces Risk Of Disease Progression Or Death By 45% Versus Venetoclax And Rituximab Alone In Previously Treated CLL/SLL Phase 3 Study

기사 요약

관련 종목

댓글 —